Core Viewpoint - Silver诺医药-B (02591) has successfully completed its global offering, raising approximately HKD 635 million through the issuance of 36.56 million shares at a final price of HKD 18.68 per share [1] Summary by Category Offering Details - The global offering consisted of 36.56 million shares, with 10% allocated for public offering in Hong Kong and 90% for international offering [1] - The final offer price was set at HKD 18.68 per share, resulting in net proceeds of approximately HKD 635 million from the global offering [1] Subscription Demand - The Hong Kong public offering was oversubscribed by 5,341.66 times, indicating strong demand from local investors [1] - The international offering saw a subscription rate of 10.67 times, reflecting significant interest from international investors [1] Trading Information - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on August 15, 2025, at 9:00 AM [1]
银诺医药-B(02591)：香港公开发售获5341.66倍认购